Immunome, Inc.
IMNM
$19.37
$2.2813.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 37.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 37.22% | |||
| Cost of Revenue | 21.61% | 9.71% | |||
| Gross Profit | -35.01% | -7.34% | |||
| SG&A Expenses | 8.99% | -6.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.10% | 6.16% | |||
| Operating Income | -29.39% | -4.13% | |||
| Income Before Tax | -32.40% | -4.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.40% | -4.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.40% | -4.22% | |||
| EBIT | -29.39% | -4.13% | |||
| EBITDA | -29.90% | -4.12% | |||
| EPS Basic | -30.95% | 4.88% | |||
| Normalized Basic EPS | -30.99% | 4.88% | |||
| EPS Diluted | -30.95% | 4.88% | |||
| Normalized Diluted EPS | -30.99% | 4.88% | |||
| Average Basic Shares Outstanding | 1.09% | 9.57% | |||
| Average Diluted Shares Outstanding | 1.09% | 9.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||